Higher predictiveness and reliability in therapeutic antibody preclinical testing
In collaboration with Quadira Biosciences, abc biopply has successfully developed and validated a new 3D in vitro test series for preclinical characterization of the effectiveness and functionality of novel therapeutic antibody-drug-conjugates.
Those unique tests have been specifically developed on the 3D CoSeedis™ technology platform. They replace and outperform the current standard PDX systems not only in terms of accuracy, but also by reducing the duration of the experiment and the resources required to do so.
In particular, abc biopply developed and validated the following specific assays:
In chip 3D viability assay: performed simultaneously on 680 synchronised micro-tumours
In chip 3D apoptosis assay: performed simultaneously on 680 synchronised micro-tumours
In chip dose response curves: performed on 680 individual synchronised mircro-tumours
In chip tumour relapse assay: to measure long term effectiveness of drug treatment on quiescent tumor cells based on the behaviour of 900 micro-tumours
One-step drug/antibody penetration experiment: performed on up to 680 micro-tumours
Would you like us to test your antibodies or chemical compounds? Or are you interested to see how abc biopply’s expertise and technology could optimise your drug development process? I am looking forward to answering your call.
Best regards
Marco Leu, PhD Sales & Operation abc biopply ag Direct Email / Phone +41 (0)79 834 95 56
